Biochemical Failure after Radical Prostatectomy in Men with Pathologic Organ-Confined Disease: pT2a versus pT2b

Cancer

Volumn 100, Issue 8, 2004, Pages 1646-1649

  Freedland, Stephen J ^a,b,c,d   Partin, Alan W ^a,b   Epstein, Jonathan I ^a,b   Walsh, Patrick C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Prostate carcinoma; Prostate specific antigen; Radical prostatectomy; TNM stage

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; SURVIVAL RATE;

AGED; CARCINOMA; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 1842582045     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20145     Document Type: Article

References (10)

1. Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC cancer staging manual (5th edition). Philadelphia: Lippincott-Raven, 1998.
2. Freedland SJ, Presti JC Jr., Terris MK, et al. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol. 2003;169:2129-2135.
3. Han M, Walsh PC, Partin AW, Rodriguez R. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for Stage T2 disease. J Urol. 2000;164:89-92.
4. Sanda M, Dash A, Wei JT, Dunn R, Rubin MA. Recommendations for modifying the 2002 AJCC pathology staging system based on accuracy in reflecting prognosis. J Urol. 2003; 169:290.
5. May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer staging system to predict progression-free survival after radical prostatectomy. BJU Int. 2001; 88:702-707.
6. Cagiannos I, Graefen M, Karakiewicz PI, et al. Analysis of clinical Stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol. 2002;20: 2025-2030.
7. Salomon L, Levrel O, Anastasiadis AG, et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol. 2003;43:39-44.
8. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264-269.
9. Carvalhal GF, Humphrey PA, Thorson P, Yan Y, Ramos CG, Catalona WJ. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer. 2000;89:1308-1314.
10. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528-534.